Published in: Journal of Controlled Release
Authors: Pieter B.A.A. van Driel, Martin C. Boonstra, Maxime D. Slooter, Raimond Heukers, Marieke A. Stammes, Thomas J.A. Snoeks, Henriette S. de Bruijn, Paul J. van Diest, Alexander L. Vahrmeijer, Paul M.P. van Bergen en Henegouwen, Cornelis J.H. van de Velde, Clemens W.G.M. Löwik, Dominic J. Robinson, Sabrina Oliveira
Photodynamic therapy (PDT) induces cell death through local light activation of a photosensitizer (PS) and has been used to treat head and neck cancers. Yet, common PS lack tumor specificity, which leads to collateral damage to normal tissues. Targeted delivery of PS via antibodies has pre-clinically improved tumor selectivity.
The research group used ML7710 series lasers to study EGFR-targeted nanobody-IRDye700DX conjugates for H&N cancer PDT using mouse tumor models.
